Mitochondrial Biomarker Stratification for CNS Disease Precision Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches lack effective methods to identify and tailor metabolic interventions for mitochondrial dysfunction in neurodegenerative and neuropsychiatric diseases, which are characterized by progressive neuronal loss and mitochondrial defects, necessitating a precision medicine approach to stratify patients and treat metabolic defects.
Innovation Solution
A method involving metabolomics and genetic analyses to identify mitochondrial biomarker metabolites and genetic markers, allowing for the stratification of patients and the administration of targeted therapies to correct metabolic defects related to mitochondrial dysfunction, including the use of PPAR agonists, ketone bodies, and other compounds to modulate mitochondrial energetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional diagnostic methods are used for CNS diseases, then treatment approaches are generic and not tailored to individual patients, but this fails to address the heterogeneity of mitochondrial dysfunction across different patient subgroups
Solution Approach 1:
The patent segments patients with CNS diseases into distinct subgroups based on their mitochondrial metabolic profiles. By dividing the heterogeneous patient population into smaller, more homogeneous groups characterized by specific metabolic signatures (e.g., defects in beta-oxidation, TCA cycle, or electron transport chain), the methodology enables personalized treatment strategies tailored to each subgroup's specific metabolic defects rather than applying generic treatments to all patients.
Solution Approach 2:
The patent utilizes changes in metabolic parameters (levels of acylcarnitines, ketone bodies, amino acids, and other metabolites) as diagnostic markers to stratify patients. By measuring and comparing these biochemical parameters against reference ranges, the system identifies specific metabolic abnormalities that characterize different patient subgroups, enabling precision medicine approaches for CNS disease treatment.
2Measurement precision
If metabolomics and genetic analyses are implemented to identify mitochondrial biomarkers, then patient stratification and precision treatment become possible, but the complexity and cost of diagnostic procedures increase
Solution Approach 1:
The patent employs universal analytical platforms (mass spectrometry and genetic sequencing) that can simultaneously analyze multiple metabolic parameters and genetic markers across different patient samples. These multi-functional systems enable comprehensive metabolic profiling (detecting acylcarnitines, ketone bodies, amino acids, lipids) and genetic analysis in a single integrated workflow, achieving high measurement precision while consolidating diagnostic capabilities into unified analytical instruments.
Solution Approach 2:
The patent uses metabolic biomarkers (acylcarnitines, ketone bodies, amino acids) as intermediary molecules that reflect underlying mitochondrial dysfunction. These measurable metabolites serve as proxies for complex mitochondrial defects, allowing indirect but accurate identification of metabolic abnormalities without requiring direct observation of mitochondrial function. This intermediary approach simplifies the diagnostic challenge by translating complex cellular defects into measurable biochemical signatures.
3Reliability
If targeted therapies are administered based on metabolic profiling, then treatment effectiveness is improved for specific patient subgroups, but the time and resources required for comprehensive metabolic analysis increase
Solution Approach 1:
The patent performs preliminary metabolic profiling and genetic analysis during the diagnostic phase to identify mitochondrial defects before treatment initiation. By conducting comprehensive metabolic screening (measuring acylcarnitine profiles, ketone bodies, amino acids) and genetic testing in advance, the system determines appropriate targeted therapies beforehand, avoiding trial-and-error treatment approaches and enabling patients to receive effective treatments from the outset.
Solution Approach 2:
The patent implements a feedback mechanism where treatment responses are monitored through repeated metabolic measurements. By tracking changes in metabolic biomarkers (acylcarnitine levels, ketone body concentrations) over time, the system provides feedback on treatment effectiveness, allowing clinicians to adjust therapies based on actual metabolic responses and ensure continued treatment efficacy for each patient subgroup.
Data Source
AI summary
Described herein are methods for identifying mitochondrial defects using metabolomics and genetic analyses and using this information to stratify patients and to correct for metabolic defects in a precision medicine approach. One embodiment is a method for isolating and analyzing samples containing one or more mitochondrial biomarker metabolites or genetic markers useful for the analysis, identification, stratification or classification, and treatment of metabolic changes associated with a CNS or neuropsychiatric disease in a subject and therapies useful for the treatment thereof. In one aspect, the biomarker metabolites comprise mitochondrial metabolites including acylcarnitines and endocannabinoids and the genetic analyses focus on metabolic enzymes or transport mechanisms.